Page 6 - போஹெரிங்கர் இஂகல்‌ஹைம் மருந்துகள் இன்க் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Health your username 4 hours ago On Tuesday in the District of Delaware, Boehringer Ingelheim Pharmaceuticals Inc. (BIPI) and its affiliates filed a complaint against a generic drug manufacturer with allegations that the generic company has infringed the plaintiffs’ patents covering diabetes drug Trijardy XR. The plaintiffs own or are assignees of United States Patent Nos. 8,551,957; 9,155,705; 9,415,016; 9,949,998; 10,022,379; 10,258,637; and 10,406,172 covering Trijardy XR, all of which were issued by the U.S. Patent and Trademark Office between 2013 and 2019, the complaint said. BIPI also holds New Drug Application (NDA) No. 212614 for empagliflozin-linagliptin-metformin hydrochloride extended-release tablets in various dosages, sold under the brand name product. The plaintiffs’ drug patent information is listed in the Food and Drug Administration (FDA)’s database

United statesTrademark officeU lupin pharmaceuticals incBoehringer ingelheim pharmaceuticals incDrug administrationLupin ltdBoehringer ingelheim pharmaceuticalsUnited states patentNew drug applicationLupin pharmaceuticals incAbbreviated new drug applicationஒன்றுபட்டது மாநிலங்களில்முத்திரை அலுவலகம்போஹெரிங்கர் இஂகல்‌ஹைம் மருந்துகள் இன்க்லூபின் லிமிடெட்போஹெரிங்கர் இஂகல்‌ஹைம் மருந்துகள்